Table 1.
Efficacy Outcomes of Amivantamab-vmjw for NSCLC Harboring EGFR Exon20ins Mutations [8].
| Response | CR No. (%) | PR No. (%) | SD No. (%) | PD No. (%) | ORR % (95% CI) | NE No. (%) | mPFS(95% CI) | mOS(95% CI) |
|---|---|---|---|---|---|---|---|---|
| Efficacy population (n = 81) | 3 (4) | 29 (36) | 39 (48) | 8 (10) | 40 (29–51) | 2 (2) | 8.3 mo (6.5–10.9) |
22.8 mo (14.6-NR) |
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, overall response rate; NE, not evaluable; mPFS, median progression-free survival; mo. Months; mOS, median overall survival; NR, not reached; NSCLC, non-small cell lung cancer.